Juhi R. Uttamani

Juhi R. Uttamani

Auto-generated profile, based on publicly available information

Juhi R. Uttamani

Department of Periodontics, College of Dentistry University of Iowa Iowa City Iowa USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
JUJuhi R. Uttamani
Juhi R. Uttamani
VKVarun Kulkarni
Varun Kulkarni
AVAraceli Valverde
Araceli Valverde
RNRaza Ali Naqvi
Raza Ali Naqvi
TDThomas Van Dyke
Thomas Van Dyke
Afsar NaqviAfsar Naqvi
Afsar Naqvi
Aim: Polarization of macrophages (Mφ) is a well‐controlled axis with considerable consequences in both the pro‐inflammatory and resolution phases of inflammation. We aimed to determine if periodontal therapy may instigate M1 to M2 Mφ polarization favoring resolution of inflammation within periodontal tissues.Methods: Gingival biopsies were excised from subjects diagnosed with Stage III, Grade B periodontitis before and 4–6 weeks after nonsurgical periodontal therapy. Total RNA was isolated and pro‐ and anti‐inflammatory markers associated with Mφ polarization assessed by RT‐qPCR. Mice were subject to ligature‐induced periodontitis and gingival tissues collected after 8 days in‐situ or 10 days after ligature removal and M1 and M2 Mφ markers examined by RT‐qPCR and flow cytometry.Results: In human samples, improvement in clinical parameters posttherapy correlates with reduced bacterial burden, downregulation in M1 (TNF‐α, STAT1, CXCL10, and miR‐155), and elevated levels of M2 (STAT6, TGM2, CCL22, and IL‐10) Mφ markers. In a murine model of resolution of LIP, we observed reduced levels of M1 Mφ markers cox2, iNOS2, F4/80+CD80+, and F4/80+CD86+ and elevated levels of M2‐like Mφ markers tgm2, arg1, F4/80+CD206+ and F4/80+CD163+ corroborated human findings.Conclusion: Resolution of periodontal inflammation is associated with M1 to M2 Mφ polarization after nonsurgical periodontal therapy. Assessment of Mφ markers can provide relevant clinical information on the successful response of periodontal therapy and may be used to target nonresponders.

7 July 2020
Verified
Preprint
Open access
JUJuhi Uttamani
Juhi Uttamani
GFGabriela Fernandes
Gabriela Fernandes
SPShivani Pandey
Shivani Pandey
VSVenkatasruthi Surabathula
Venkatasruthi Surabathula
DBDivya Bhat
Divya Bhat
Several strains of the novel Coronavirus have been identified and countries around the world are conducting research to identify, map and compare each type. Its infection can manifest with symptoms ranging from uncomplicated non-specific illness to a more damaging syndrome that include mild to moderate pneumonia (Co-vid 19 pneumonia broadly categorised into the phenotypes: L-type and H-type); Acute Respiratory Distress Syndrome; Sepsis and Septic shock. Although, this virus has a low mortality rate, the danger lies in its virulence and transmission dynamics. With more and more cases being reported, researchers and clinicians are promptly identifying and triaging the cases for treatment. Till date, there has been no drug identified to be efficacious cure for this infection. Using the WHO guidelines as a base, various medical institutions are continuously updating their guidelines for the identification and therapeutic management of persons infected with Co-vid 19, with a strong emphasis on IPC measures. The guidelines also highlight detailed supportive treatment including supplemental oxygen therapy, ventilation, intubation and management of specific complications. The current treatment is tailored to patient centred management for the existing co-morbidities and appreciate a progress in the prognosis. What is needed at this hour however, is a definitive drug therapy or vaccine. Different countries are rushing to find this and various trials are already underway. The aim of this article is thus to review salient features of specific therapies being used now and summarise the different clinical trials being conducted so as to stay abreast of the possible treatment modalities.